Analysis of influencing factors for concurrent myocardiac injury in patients with malignant tumor during paclitaxel chemotherapy
Objective To analyze the influencing factors for concurrent myocardial injury in malignant tumor patients during paclitaxel chemotherapy.Methods A total of 110 malignant tumor patients who received paclitaxel chemotherapy at Jianyang People's Hospital from September 2017 to September 2022 were selected.Clinical data of the patients were retrospectively analyzed.Patients were divided into two groups:35 patients with myocardial injury in the observation group and 75 patients without myocardial injury in the control group.Clinical data between the two groups were compared.Factors with differences in univariate analysis were included in a multivariate Logistic regression model to analyze the influencing factors for concurrent myocardial injury in patients with malignant tumors during paclitaxel chemotherapy.Results Among 110 malignant tumor patients receiving paclitaxel chemotherapy,35 cases(31.82%)experienced myocardial injury,while 75 cases(68.18%)did not.Univariate analysis showed that there were statistically significant differences in age,history of hypertension,gender,history of diabetes,obesity,B-type natriuretic peptide(BNP),cardiac troponin I(cTnI),C-reactive protein(CRP),single dose of paclitaxel,cumulative dose of paclitaxel,treatment cycle,and dosage regimen between the two groups(t/χ2=5.682,4.716,5.858,6.074,10.174,120.005,46.687,10.430,5.002,4.604,5.170,5.303;P<0.05).Multivariate Logistic regression analysis showed that age≥65 years old,BNP,cTnI,CRP,single dose of paclitaxel,cumulative dose of paclitaxel,treatment cycle and dosage regimen were influencing factors for myocardiac injury in malignant tumor patients receiving paclitaxel[OR(95%CI)=3.080(1.747-4.413),1.984(1.488-2.480),1.856(1.244-2.467),1.728(1.467-1.989),1.853(1.132-2.575),9.393(8.509-10.277),4.618(3.844-5.392),4.272(3.190-5.354);P<0.05].Conclusion Age≥65 years old,BNP,cTnI,CRP,single dose of paclitaxel,cumulative dose of paclitaxel,treatment cycle and dosage regimen are influencing factors for myocardiac injury in patients with malignant tumors during paclitaxel chemotherapy.Clinicians should pay attention to these factors when using paclitaxel therapy to reduce the risk of myocardial injury.
国家科技期刊平台
NSTL
万方数据
